|
A Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome (CA-4948-102) |
I |
|
|
A Trial of Atezolizumab Plus Chemotherapy After Progression on Single Agent PD-1 or PD-L1 Inhibitor in Cisplatin-Ineligible Patients with Advanced Urothelial Carcinoma (GU17-295) |
II |
|
|
Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients (ASSURE) |
|
|
|
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (A151216) |
III |
|
|
An Observational Study Assessing the Clinical Effectiveness of the VeriStrat Test and Validating Immunotherapy tests in Subjects with NonSmall Cell Lung Cancer (BDX-00146) |
|
|
|
An Open Label Study of Intratumoral Tavo Plus Electroporation in Combination with Pembrolizumab in Patients with Stage III/IV Melanoma who are Progressing on either Pembrolizumab or Nivolumab Treatment (PISCES) |
II |
|
|
An Open Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, An Anti-CD20 X Anti-CD3 Bispecific Antibody in Patients with Relapsed/Refractory Follicular Lymphoma (R19179-ONC-1625) |
|
|
|
An Open Label Study to Assess the Safety and Tolerability and Pharmacokinetics of Capivasertib in Combination with Novel Agents in Patients with Castration Resistant Prostate Cancer (D3618C00002) |
I |
|
|
An Open Label Study to Investigate the Efficacy and Safety of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Patients with Stage IB, II, IIIA, or Selected IIIB Resectable and Untreated NonSmall Cell Lung Cancer (GO40241) |
|
|
|
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery (GU002) |
III |
|
|
BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer |
|
|
|
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (19144) |
|
|
|
Blood Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors |
III |
|
|
Clinical Trial Evaluating Post- Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After (B51) |
III |
|
|
Clinical Validation of the InterVenn Ovarian CAncer Liquid Biopsy: VOCAL Study (OVACA-001) |
|
|
|
Crizotinib vs Placebo for Patients with Tumors Harboring the ALK Fusion Protein (E4512) |
III |
|
|
De-Escalation Protocol of HPV Mediated Oropharyngeal Squamous Cell Carcinaoma Based on the American Joint Committee on Cancer Care 8th Edition Staging Manual (MECC-HN01) |
|
|
|
Development and Validation of a Multiplex qPCR Short Fragment Cell Free DNA Assay as a potential biomarker for predicting Early Non-Response to therapy in Metastatic Cancer (CADEX-001) |
|
|
|
Expanded Access Program for belantamab mafodotin in Patients with Relapsed/Refractory Multiple Myeloma who are Refractory to a Proteasome Inhibitor, and an Immunomodulatory Agent, and an Anti-CD38 Antibody (213304) |
|
|
|
First in Human, Open Label, Dose Escalation Trial with Expansion Cohorts to Evaluate Safety of GEN1029 in Patents with Malignant Solid Tumors (GCT1029-01) |
|
|
|
Integrated Cancer Repository for Cancer Research (iCaRe2) – Breast Cancer Collaborative Repository - BCCR |
III |
|
|
International Study Of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) For The Treatment Of Patients With Unresected Stage I/II, Lymph-Node Negative Non-Small Cell Lung Cancer (R3515) |
III |
|
|
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab (LU005) |
II |
|
|
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Trial in Small-Cell Lung Cancer (S1827) |
III |
|
|
Nivolumab and Ipilimumab Followed by Nivolumab vs Cabozantinib with Nivolumab: A Trial in Metastatic Untreated Renal Cell Cancer (A031704)[PDIGREE] |
III |
|
